Navigation Links
Breast Cancer May Be 'Uniquely Sensitive' To Inhibitors Of PI3K Pathway

"Because up to 75 percent of breast cancer patients have an abnormality in a specific cell signaling pathway, drugs that target different molecules along that pathway may be especially effective for treating the disease, says a researcher from The University of Texas M. D. Anderson Cancer Center."

A clearer picture is now emerging about the importance of the phosphatidylinositol 3 kinase (PI3K) pathway to breast cancer development, says Gordon Mills, M.D., Ph.D., a professor and chair of the Department of Molecular Therapeutics. This pathway, which is linked to critical growth factor receptors and is involved in programmed cell death, is aberrant at multiple levels in breast cancer, including mutations in PI3K itself or its many “downstream?players, such as PTEN, or AKT. “There is a lot of crosstalk between the PI3K pathway and other pathways, a lot of feed-forward and feedback loops,?says Mills. “But I and others believe there are central nodes between these intersecting circles that can be effectively targeted with drugs.?Only one PI3K pathway inhibitor is in use to date, but others are increasingly being developed and tested, says Mills, who is discussing the importance of this pathway at the annual San Antonio Breast Cancer Symposium meeting. “At least 20 different companies have recognized the importance of the pathway in breast cancer and are trying to develop drugs that target it.?In the future, breast cancer tissue samples from newly diagnosed patients can be tested for their specific PI3K pathway abnormality in order to find a drug that zeroes in on what may be the cancer’s Achilles?heel, Mills says. “Using those drugs in combination with other treatments such as chemotherapy may significantly advance breast cancer care,?he says.
'"/>

Source:Press release from The University of Texas M. D. Anderson Cancer Center


Page: 1

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
3. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
4. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
5. New Breast Cancer Test Could Save Lives
6. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
7. Nanoparticle Breast Cancer Drug Approved by FDA
8. Genpathway and Baylor College of Medicine Identify New Genes in Breast Cancer
9. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
10. Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics
11. Antiretroviral Therapy May Prevent HIV Transmission From Breastfeeding Mothers To Infants

Post Your Comments:
(Date:11/9/2009)... inspired a 3.2m, three-year research project that...ecurity, energy and the environment. The Universit...inetiQ have just signed a collaborative contract t... physical sciences research. , Over the next th... of Exeter and QinetiQ will work together to devel...
(Date:11/9/2009)...eaders from around the world will gather in Boston...r Targets and Cancer Therapeutics International Co...ation on important cancer therapies in development...t effectively we need a greater understanding of t...l," said Lewis Cantley, Ph.D., director of the can...
(Date:11/8/2009)...S WITH INTELLECTUAL DISABILITIES: AN OPPORTUNITY F...y involving adults with intellectual disabilities ...lth knowledge after taking a semi-weekly class for...ly accepted term for mental retardation, have slig...and preventable chronic diseases compared to the g...
Breaking Biology News(10 mins):£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 3Nevada Drug Card and Las Vegas Chamber Offer Rx Assistance 52973 1Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 1Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 2Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 3Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 4New drug for children with high risk leukemia 52965 1New drug for children with high risk leukemia 52965 2
... of a sustainable biofuels industry in Tennessee h... of Energy has announced that Mascoma Corporation,...cipients of a $26 million grant for the developmen...s for demonstrating the production of cellulosic e... operations. The facility is to be constructed at ...
..., including malaria, dengue fever, and avian influ...l factors and, more recently, to climate change. R...e animals that carry and ultimately transmit these...occurs, these diseases may be introduced into area...standing the interactions that occur among climate...
...nse of Arctic sea ice is increasingly vulnerable t...dy, by scientists at the National Center for Atmos...ty (CSU), finds that unusually sunny weather contr... while similar weather conditions in past summers ...he study, which draws on observations from instrum...
Other Biology News:Mascoma and UT join in $26M DOE grant 2Mascoma and UT join in $26M DOE grant 3Scientists to explore global change-public health connection 2Arctic ice more vulnerable to sunny weather, new study shows 2Arctic ice more vulnerable to sunny weather, new study shows 3
(Date:11/5/2009)...ORDOVA, Calif., Nov. 5 T...plier of innovative products for processing and st... the first quarter of fiscal 2010. ,, For the q...ted revenues of $5.2 million, a 15 percent increas...er a year ago. The Company said the key contributo...
(Date:11/5/2009)...eb., Nov. 5 Transgenomic...financial results for the quarter ended September ...ented in the tables that follow. ,, Third Quar... $366,000 or $0.01 per share for the third quarter...$0.01 per share for the third quarter of 2008. ,...
(Date:11/5/2009)...E, Calif., Nov. 5 Cephei...ives will be speaking at the following investor co...a webcast. , , Credit Suisse Healt...rsday, 12 November, 2009 at 10 a.m. Mountain Time,..., London, England, Tuesday, 1 Dece...
(Date:11/5/2009)...O, CA, November 5, 2009 ...on using proprietary taste receptor-based technolo...food, beverage, and ingredient supply industries, ...ancial results for the third quarter ended Septemb...hird quarter of 2009, compared to $4.0 million for...
Breaking Biology Technology:ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7Cepheid to Webcast Upcoming Financial Presentations 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...RDAM, The Netherlands, February 11, Agendia, a wor...nounced the appointment of Alan B. Carter as the c...elopment. , "As we continue to grow as a globa...primary aims," commented Dr. Bernhard Sixt, Ph.D.,...sive business development expertise will,strengthe...
... (Pink Sheets: MNCN), a global health company that...ce positive, long term benefit to the agricultural... executed its definitive agreement to acquire Modu...ice of $500,000 in the form of Convertible Preferr...will allow Mach One to bring in house the engineer...
...A team of Los Alamos researchers led by Victor Kli...oton creates multiple electronsis a real phenomeno...bservation born of extraneous effects that mimic c...a recent issue of Accounts of Chemical Research ,...more than one unit of energy per photon. , Questi...
Other Biology Technology:Agendia Appoints VP of Business Development 2Mach One Executes Definitive Agreement to Acquire Biopharmaceutical Design & Engineering Firm 2Research highlights potential for improved solar cells 2Research highlights potential for improved solar cells 3
HV Mini 5 (230V / 50Hz) from Thermo Scientific
Immulon 1 B 1x12 Strip from Thermo Scientific
Peptides from Thermo Scientific
RapidStak 2 (requires 4 staks, not included) from Thermo Scientific
Biology Products: